Press release
Nasopharyngeal Carcinoma Market to Expand Significantly by 2034, States DelveInsight Report | BieGene, Famitinib, Tessa Therapeutics, Chia Tai Tianqing Pharma, Novartis, Harbour BioMed
The Nasopharyngeal Carcinoma market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage pipeline products will significantly revolutionize the Nasopharyngeal Carcinoma market dynamics.
DelveInsight's "Nasopharyngeal Carcinoma Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Nasopharyngeal Carcinoma, historical and forecasted epidemiology as well as the Nasopharyngeal Carcinoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Nasopharyngeal Carcinoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Nasopharyngeal Carcinoma Market Forecast [https://www.delveinsight.com/sample-request/nasopharyngeal-carcinoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key facts of the Nasopharyngeal Carcinoma Market Report
*
The Nasopharyngeal Carcinoma market size is anticipated to grow with a significant CAGR during the study period (2020-2034).
*
In July 2025, The European Commission has granted approval for tislelizumab-jsgr (Tevimbra) in combination with cisplatin and gemcitabine as a first-line treatment for adults with recurrent or metastatic nasopharyngeal carcinoma (NPC) who are not eligible for curative surgery or radiotherapy, as announced in a press release by BeOne Medicines.
*
In April 2025, The FDA approved a new treatment for adults with non-keratinizing nasopharyngeal carcinoma (NPC), a rare head and neck cancer. Clinical trials showed that patients receiving the drug, penpulimab, had longer progression-free survival compared to those on standard therapies. Penpulimab is intended for advanced, recurrent, or metastatic NPC and can be used in combination with standard chemotherapy as a first-line option or as a standalone therapy in patients previously treated with other regimens.
*
As per the studies of the National Health Services (NHS), men are affected about 3 times more than women by nasopharyngeal cancer
*
A higher number of patients diagnosed with Nasopharyngeal Carcinoma are above the age of 65 or older
*
The global prevalence of Nasopharyngeal Carcinoma is 1.2 persons among 100,000 people
*
In the United States, the incidence of Nasopharyngeal Carcinoma is 7 cases diagnosed per 1 million people annually
*
Key Nasopharyngeal Carcinoma Companies: Akeso Tiancheng, Inc, Chia Tai Tianqing Pharmaceutical, Hoffmann-La Roche, Novartis, Jiangsu HengRui Medicine, Qilu Pharmaceutical, Akeso, Bristol-Myers Squibb, Sanofi, Innovent Biologics (Suzhou) Co. Ltd., Eli Lilly and Company, and others
*
Key Nasopharyngeal Carcinoma Therapies: AK105, TQB2618, Gemcitabine, Zometa (zoledronic acid), SHR-1210, QL1706, Penpulimab, Nivolumab, Docetaxel, Sintilimab, Pemetrexed (Alimta), and others
*
The Nasopharyngeal Carcinoma epidemiology based on gender analyzed that the prevalence of Nasopharyngeal Carcinoma is commonly more in males than females
Nasopharyngeal Carcinoma Overview
Nasopharyngeal Carcinoma (NPC) is a rare type of head and neck cancer that originates in the nasopharynx, the upper part of the throat located behind the nose. NPC is strongly associated with Epstein-Barr virus (EBV) infection and is more common in Southeast Asia, North Africa, and Southern China. Risk factors include genetics, certain diets (like salted fish), and environmental exposures. Symptoms may include a lump in the neck, nasal congestion, hearing loss, or nosebleeds. NPC is often treated with radiation therapy, chemotherapy, or a combination of both, especially in advanced stages. Early detection improves outcomes.
Request a sample for the Nasopharyngeal Carcinoma Market Report:
https://www.delveinsight.com/report-store/nasopharyngeal-carcinoma-market [https://www.delveinsight.com/report-store/nasopharyngeal-carcinoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Nasopharyngeal Carcinoma Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Nasopharyngeal Carcinoma Epidemiology Segmentation:
The Nasopharyngeal Carcinoma market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
*
Total Prevalence of Nasopharyngeal Carcinoma
*
Prevalent Cases of Nasopharyngeal Carcinoma by severity
*
Gender-specific Prevalence of Nasopharyngeal Carcinoma
*
Diagnosed Cases of Episodic and Chronic Nasopharyngeal Carcinoma
Download the report to understand which factors are driving Nasopharyngeal Carcinoma epidemiology trends @ Nasopharyngeal Carcinoma Epidemiological Insights [https://www.delveinsight.com/sample-request/nasopharyngeal-carcinoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Nasopharyngeal Carcinoma Market
The dynamics of the Nasopharyngeal Carcinoma market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as Gemcitabine, Cisplatin, and others during the forecasted period 2020-2034.
Nasopharyngeal Carcinoma Therapies and Key Companies
*
AK105: Akeso Tiancheng, Inc
*
TQB2618: Chia Tai Tianqing Pharmaceutical
*
Gemcitabine: Hoffmann-La Roche
*
Zometa (zoledronic acid): Novartis
*
SHR-1210: Jiangsu HengRui Medicine
*
QL1706: Qilu Pharmaceutical
*
Penpulimab: Akeso
*
Nivolumab: Bristol-Myers Squibb
*
Docetaxel: Sanofi
*
Sintilimab: Innovent Biologics (Suzhou) Co. Ltd.
*
Pemetrexed (Alimta): Eli Lilly and Company
To know more about Nasopharyngeal Carcinoma treatment, visit @ Nasopharyngeal Carcinoma Medications [https://www.delveinsight.com/sample-request/nasopharyngeal-carcinoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Scope of the Nasopharyngeal Carcinoma Market Report
*
Study Period: 2020-2034
*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
*
Key Nasopharyngeal Carcinoma Companies: Akeso Tiancheng, Inc, Chia Tai Tianqing Pharmaceutical, Hoffmann-La Roche, Novartis, Jiangsu HengRui Medicine, Qilu Pharmaceutical, Akeso, Bristol-Myers Squibb, Sanofi, Innovent Biologics (Suzhou) Co. Ltd., Eli Lilly and Company, and others
*
Key Nasopharyngeal Carcinoma Therapies: AK105, TQB2618, Gemcitabine, Zometa (zoledronic acid), SHR-1210, QL1706, Penpulimab, Nivolumab, Docetaxel, Sintilimab, Pemetrexed (Alimta), and others
*
Therapeutic Assessment: Nasopharyngeal Carcinoma current marketed and Nasopharyngeal Carcinoma emerging therapies
*
Migraine Market Dynamics: Nasopharyngeal Carcinoma market drivers and barriers
*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
*
Unmet Needs, KOL's views, Analyst's views, Nasopharyngeal Carcinoma Market Access and Reimbursement
Discover more about therapies set to grab major Nasopharyngeal Carcinoma market share @ Nasopharyngeal Carcinoma market forecast [https://www.delveinsight.com/sample-request/nasopharyngeal-carcinoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Nasopharyngeal Carcinoma Market Report Introduction
2. Executive Summary for Nasopharyngeal Carcinoma
3. SWOT analysis of Nasopharyngeal Carcinoma
4. Nasopharyngeal Carcinoma Patient Share (%) Overview at a Glance
5. Nasopharyngeal Carcinoma Market Overview at a Glance
6. Nasopharyngeal Carcinoma Disease Background and Overview
7. Nasopharyngeal Carcinoma Epidemiology and Patient Population
8. Country-Specific Patient Population of Nasopharyngeal Carcinoma
9. Nasopharyngeal Carcinoma Current Treatment and Medical Practices
10. Nasopharyngeal Carcinoma Unmet Needs
11. Nasopharyngeal Carcinoma Emerging Therapies
12. Nasopharyngeal Carcinoma Market Outlook
13. Country-Wise Nasopharyngeal Carcinoma Market Analysis (2020-2034)
14. Nasopharyngeal Carcinoma Market Access and Reimbursement of Therapies
15. Nasopharyngeal Carcinoma Market drivers
16. Nasopharyngeal Carcinoma Market barriers
17. Nasopharyngeal Carcinoma Appendix
18. Nasopharyngeal Carcinoma Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=nasopharyngeal-carcinoma-market-to-expand-significantly-by-2034-states-delveinsight-report-biegene-famitinib-tessa-therapeutics-chia-tai-tianqing-pharma-novartis-harbour-biomed]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Nasopharyngeal Carcinoma Market to Expand Significantly by 2034, States DelveInsight Report | BieGene, Famitinib, Tessa Therapeutics, Chia Tai Tianqing Pharma, Novartis, Harbour BioMed here
News-ID: 4118853 • Views: …
More Releases from ABNewswire
Denver's Best Appliance Repair Responds to Rising Demand for Emergency Appliance …
Denver's Best Appliance Repair expands emergency services across the Denver metro with same-day repairs, 7-day availability, 5-year parts warranty, and professional licensed technicians serving residential and commercial clients.
Household appliance failures don't follow a schedule. When a refrigerator stops cooling in the middle of summer or a washing machine floods a basement on a Sunday evening, families need immediate help. Denver's Best Appliance Repair has responded to this growing need by…
Oak Hill Clinic Reaches 30,000 Client Milestone with Results-Driven Deep Tissue …
Deep Relief in Oak Hill, Austin, has served 30,000 clients through specialized massage, chiropractic, and acupuncture care. The clinic accepts insurance and focuses on results-driven treatments for pain relief.
Deep Relief, an Oak Hill-based wellness clinic, has achieved a significant milestone by serving more than 30,000 clients seeking Relief from chronic pain, muscle tension, and mobility issues. The clinic's success stems from its commitment to advanced, results-focused bodywork that goes beyond…
Vertex Fleet Expands Nationwide Network to Combat Growing Trailer Drop Yard Shor …
Vertex Fleet announces major expansion of secure parking facilities nationwide, addressing the critical shortage of commercial vehicle storage with 15+ new locations featuring 24/7 security and technology-driven access.
The freight and logistics industry faces a mounting crisis as demand for secure parking spaces continues to outpace supply across the United States. Vertex Fleet [https://www.vertexfleet.com/], a leading provider of industrial outdoor storage solutions, has announced significant expansion plans to address this critical…
HVAC in Denver Sees Service Enhancement as Denver's Best Heating and AC Repair L …
Denver's Best Heating and AC Repair expands 24/7 emergency services across 23 metro cities, offering A+ rated heating, cooling, and commercial HVAC solutions with rapid response times and multi-brand expertise.
Denver's Best Heating and AC Repair [https://www.denversbestheatingandacrepair.com/]has expanded its service capabilities to meet growing demand for reliable heating and cooling solutions across the Denver Metro area. The A+ rated contractor now provides 24/7 emergency response services to 23 cities, addressing critical…
More Releases for Nasopharyngeal
Nasopharyngeal Swabs Market Size Unlocking New Opportunities for Success
The global nasopharyngeal swabs market was valued at approximately USD 296.8 million in 2023 and is projected to reach USD 404.1 million by 2032, growing at a compound annual growth rate (CAGR) of 6.3% from 2024 to 2032.
Request a sample copy of this report at: https://www.omrglobal.com/request-sample/nasopharyngeal-swabs-market
Nasopharyngeal Swabs Market Overview:
The nasopharyngeal swabs market is experiencing significant growth due to the increasing demand for accurate diagnostic tools in the healthcare sector. These…
Nasopharyngeal Carcinoma Treatment Market Outlook 2024: Innovations and Forecast
"The Business Research Company recently released a comprehensive report on the Global Nasopharyngeal Carcinoma Treatment Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
According to The Business Research Company's, The nasopharyngeal carcinoma…
Nasopharyngeal Airway Market Size 2024 to 2031.
Market Overview and Report Coverage
A nasopharyngeal airway (NPA) is a medical device used to maintain an open airway in patients who are unconscious or unable to protect their own airway. It is commonly used in emergency medical situations, such as during resuscitation or in the management of patients with trauma or airway obstructions.
The current outlook for the nasopharyngeal airway market is positive, with a projected growth rate of…
Nasopharyngeal Carcinoma Treatment Market
The latest Report Available at USD Analytics Market, "Nasopharyngeal Carcinoma Treatment Market" provides a pin-point analysis of changing competitive dynamics and a forward-looking perspective on different factors driving or restraining industry growth.
As the Political, Economic, Social, Technological, Environmental, and Legal factors continue to change, business leaders across industries have shifted focus to strategic objectives to achieve market excellence. The "Global Nasopharyngeal Carcinoma Treatment Market Size, Share Analysis with Forecast to…
Nasopharyngeal Carcinoma Treatment Market Size, Share, Outlook 2026
Nasopharyngeal carcinoma is a rare cancer, affecting the part of throat connecting nose and mouth, known as pharynx. Nasopharyngeal carcinoma are of three types, based on cell appearance under microscope. These include keratinizing squamous cell carcinoma, non- keratinizing differentiated carcinoma, and undifferentiated carcinoma. The early stage symptoms of nasopharyngeal carcinoma are bleeding nose, blockage and stuffiness in nose, persistent ear infection, hearing difficulties, and sore throat whereas, late stage symptoms…
Nasopharyngeal Cancer Market Estimated to Grow Strongly by 2022
Nasopharyngeal is a type of cancer which takes place in head or neck. It happens in nasopharynx, which is a upper part of the of the throat behind the nose. It is also called nasopharyngeal carcinoma (NPC). It has also been linked with Epstein-Barr virus.
Get access to full summary @: http://www.persistencemarketresearch.com/market-research/nasopharyngeal-cancer-market.asp
In 2015, American Society of Clinical Oncology (ASCO) estimated 3200 to be diagnosed with NPC in U.S. The prevalence rate…
